Outcome of MS relapses in the era of disease-modifying therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2377

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Outcome of MS relapses in the era of disease-modifying therapy ; volume:17 ; number:1 ; day:7 ; month:8 ; year:2017 ; pages:1-8 ; date:12.2017
BMC neurology ; 17, Heft 1 (7.8.2017), 1-8, 12.2017

Keyword: Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit

Creator: Stoppe, Muriel

Contributor: Busch, Maria
Krizek, Luise
Then Bergh, Florian
SpringerLink (Online service)

DOI: 10.1186/s12883-017-0927-x

URN: urn:nbn:de:1111-2017081711909

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Stoppe, Muriel
Busch, Maria
Krizek, Luise
Then Bergh, Florian
SpringerLink (Online service)

Other Objects (12)

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Current experimental disease-modifying therapeutics for multiple system atrophy

Lithium as a disease-modifying agent for prion diseases

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Disease-modifying factors in hereditary angioedema: an RNA expression-based screening

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Current experimental disease-modifying therapeutics for multiple system atrophy

Lithium as a disease-modifying agent for prion diseases

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Disease-modifying factors in hereditary angioedema: an RNA expression-based screening

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Current experimental disease-modifying therapeutics for multiple system atrophy

Lithium as a disease-modifying agent for prion diseases

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Disease-modifying factors in hereditary angioedema: an RNA expression-based screening

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Outcome of MS relapses in the era of disease-modifying therapy

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Current experimental disease-modifying therapeutics for multiple system atrophy

Lithium as a disease-modifying agent for prion diseases

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Disease-modifying factors in hereditary angioedema: an RNA expression-based screening

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Current experimental disease-modifying therapeutics for multiple system atrophy

Lithium as a disease-modifying agent for prion diseases

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Disease-modifying factors in hereditary angioedema: an RNA expression-based screening

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Current experimental disease-modifying therapeutics for multiple system atrophy

Lithium as a disease-modifying agent for prion diseases

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis

Disease-modifying factors in hereditary angioedema: an RNA expression-based screening

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Related objects

Reset password